Clinical Trials Logo
  1. Home
  2. Myeloid Leukemia
  3. NCT05309018
  4. Details
NCT05309018 Clinical Trial

Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML

Myeloid Leukemia Clinical Trial

— LAMIPA  

Official title:
Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients Followed for AML Treated With Oral Targeted Therapy

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05309018
Other study ID # 2021-07Obs-CHRMT
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date July 15, 2024
Est. completion date December 15, 2024

Study information
Verified date February 2023
Source Centre Hospitalier Régional Metz-Thionville
Contact Jennifer HUET
Phone 0033387553304
Email jennifer.huet@hotmail.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Advanced Practice Nurse (APN) is a new contributor in the French healthcare system. APN is part of a multidisciplinary team and aim to monitor patients under the coordination of the doctor particularly in onco-hematology. The aim of the study is to describe the different perceptions and expectations of APN monitoring according to patients with acute myeloid leukemia (AML) and their care team. This study will involve 10 patients, recruited over a provisional period of 5 months and 25 member of care team. Patients and their care team will be asked about their perceptions and expectations of APN participation in (AML monitoring) during a semi-structured interviews.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 35
Est. completion date December 15, 2024
Est. primary completion date August 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient with AML - Treated with a new targeted oral therapy as monotherapy or in combination: - Venetoclax* in combination with ivosidenib (IDH1 inhibitor) - Onureg* (azacitin: pyrimidine analogue) - Venetoclax (BCL-2 protein inhibitor) in combination with subcutaneous azacitin - Whose follow-up is provided alternately by a hematologist and an IPA. - Affiliated to a social security scheme Exclusion Criteria: - Moderate or severe cognitive impairment - Language barrier - Other communication disorders

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Interviews
Semi-structured interview about perceptions and expectations of APN participation in AML monitoring according to patient and to care team.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Centre Hospitalier Régional Metz-Thionville

Outcome
Type Measure Description Time frame Safety issue
Primary Perception of patient Semi-structured interview about perceptions and expectations of Advanced Practice Nurse (APN) participation in acute myeloid leukemia (AML) monitoring according to patient. Within 1 month
Secondary Perception of care team Semi-structured interview about perceptions and expectations of Advanced Practice Nurse (APN) participation in acute myeloid leukemia (AML) monitoring according to care team. Within 1 month
See also
  Status Clinical Trial Phase
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Terminated NCT00543972 - Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia Phase 1
Completed NCT00521664 - A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups Phase 3
Completed NCT05363488 - Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
Completed NCT01380756 - Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia Phase 1
Recruiting NCT05031897 - Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant Phase 2
Terminated NCT00126893 - Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia Phase 1
Completed NCT03613727 - Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients Phase 2
Active, not recruiting NCT04714372 - FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia Phase 1
Completed NCT02763475 - NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents Phase 2
Terminated NCT01643603 - Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Phase 1
Completed NCT00497991 - Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia Phase 1
Not yet recruiting NCT05787951 - Frequency and Risk Factors of Acute Myeloid Leukemia
Completed NCT04628338 - IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation Early Phase 1
Completed NCT02719821 - Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation N/A
Active, not recruiting NCT00111345 - Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents Phase 2/Phase 3
Completed NCT00114764 - Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML) Phase 2
Recruiting NCT05871008 - Integrated Actionable Aging Assessment for Cancer Patients Pilot N/A
Recruiting NCT03638206 - Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies Phase 1/Phase 2
Recruiting NCT05035706 - Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors Early Phase 1